Bourlon R, Gallegos C, Zárate-Osorno A, Carrillo J, Martínez M, Vázquez P, Candelaria M

Language: Spanish
References: 25
Page: 67-72
PDF size: 358.15 Kb.

ABSTRACT

Castleman's disease is an atypical lymphoproliferative disease, changes in variable, with poor prognosis without treatment. The causes of mortality in these patients include infection, renal failure and malignancies (including lymphoma and Kaposi's sarcoma). We describe the case of a male 38 years old with advanced multicentric Castleman's disease who presented with wasting syndrome and generalized lymphadenopathy, was treated with chemotherapy and monoclonal antibody anti-CD20. The knowledge and clinical suspicion of this disease is essential to allow prompt treatment and avoid complications.

REFERENCES

1. Castleman B, Towne V. Case records of the Massachusetts General Hospital: Case no 40231. N Engl J Med 1954;250:1001-1005.

2. Bowne J, Lewin JJ, Filippa DA, et al. The Management of Unicentric and Multicentric Castleman’s Disease. A Report of 16 Cases and a Review of the Literature. Cancer 1999;85:706-717.

3. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972;29:670-683.

4. Frizzera G, Peterson BA, Bayrd ED, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985;3:1202-1216.

5. Roca B. Casleman’s Disease. A Review. AIDS Rev 2009;11:3-7.

6. Casper C. New approacches for the treatment of human herpesvirus 8-associated disease. Rev Med Virol 2008;18:321-329.

7. Candelaria M, Luna-Ochoa E, Labardini-Mendez J, et al. Virus y neoplasias hematológicas. Rev del Instituto Nacional de Cancerología 2009;4:217-235.

8. Dham A, Peterson B. Castleman Disease. Curr Opin Hematol 2007;14:354-359.

9. Cronine D, Warneke WA. Castleman´s Disease. An Update on Classification and the Spectrum of Associated Lesions. Adv Anat Pathol 2009;16:236-246.

10. Stebbing J, Pantanowitz L, Dayyani F, et al. HIV-associated multicentric Castleman’s Disease. Am J Hematol 2008;83:498-503.

11. Mylona E, Baraboutis L, Lekakis L, et al. Multicentric Castleman´s Disease in HIV infection: a systemic review of the literature. AIDS Rev 2008;10:25-35.

12. Kojima M, Nakamura N, Tsukamoto N. Clinical implications of idiopathic multicentric Castleman´s Disease among Japanese: A report of 28 cases. Int J Surg Pathol 2008;16:391-398.

13. Jongsma T, Verburg R, Geelhoed-Duijvestin P. Castleman’s Disease: A rare lymphoproliferative disorder. Eur J Inter Med 2007;18:87-89.

14. González-Guerra E, Harmo MR, Fariña FC, et al. Glomeruloid haemangioma is not always associated with POEMS syndrome. Clin Exp Dermatol 2009;34:800-803.

15. Oksehendler E, Boulanger E, Galicier L. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002;99:2331-2336.

16. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523-531.

17. Coca S, Salas I, Martínez R, et.al. Meningeal Castleman’s Disease with multifocal involvement: a case report and review of the literature. J Neurooncol 2008;88:37-41.

18. Sobrevilla-Calvo P, Avilés-Salas A, Cortés-Padilla D, et al. Características clinicopatológicas de la enfermedad de Castleman´s. Experiencia en el Instituto Nacional de Cancerología. Cir Ciruj 2009;77:187-192.

19. Starkey C, Joste N, Lee F. Near total resolution of multicentric Castleman´s Disease by prolonged treatment with thalidomide. Am J Hematol 2006;81:303-304.

20. Gerard L, Berezne A, Galicier L. Prospective study of rituximab in chemotherapy-dependent HIV associated multicentric Castleman’s disease. ANRS 117 Castleman B trial. J Clin Oncol 2007;25:3350-3356.

21. Bower M, Powles T, Williams S. Brief communication: rituximab in HIV-associated multicentric Castleman´s Disease. Ann Intern Med 2007;147:836-839.

22. Stary G, Kohrgruber N, Herneth A, et al. Complete regression of HIV-associated multicentric Castleman´s Disease treated with rituximab and thalidomide. AIDS 2008;22:1232-1234.

23. Fragasso A, Mannarella C, Ciancio A, et.al. Complete remission and virologic response to combined chemoimmunotherapy (R-CVP) followed maintenance in HIV-negative, HHV-8 positive patient with multicentric Castleman´s Disease. Leuk Lymphoma 2008;49:2224-2226.

24. Matsuyama M, Suzuki T, Tsuboi H. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease. Intern Med 2007;46:771-774.

25. Casper C, Krantz E, Corey L. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind placebo controlled, crossover trial. J Infect Dis 2008;198:23-30.